BioXcel Therapeutics, Inc.

BTAI US09075P1057

BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.

Annual Performance ¹

2021	2022	2023	2024	2025
-61%	-6%	-86%	-87%	0%

Annual Insiders Turnover, USD ²

¹ annual and historical performance metrics are recalculated on a daily basis;
² represents the total value of insider transactions (both buying and selling);

Insider Activity

Person	Price	Shares	Total	Published	Completed
Steinhart Richard I CFO	0.36 USD	372 Sold	133 USD	14/12/2024	16/12/2024
O'neill Vincent O	0.35 USD	165 Sold	58 USD	14/12/2024	16/12/2024
Rodriguez Javier O	0.36 USD	220 Sold	78 USD	14/12/2024	16/12/2024
Yocca Frank CSO	0.36 USD	205 Sold	73 USD	14/12/2024	16/12/2024
Mehta Vimal CEO	0.36 USD	2,134 Sold	773 USD	14/12/2024	16/12/2024
Yocca Frank CSO	0.35 USD	225 Sold	79 USD	14/12/2024	16/12/2024
Mehta Vimal CEO	0.36 USD	983 Sold	358 USD	14/12/2024	16/12/2024
Rodriguez Javier O	0.36 USD	210 Sold	75 USD	14/12/2024	16/12/2024
Steinhart Richard I CFO	0.36 USD	205 Sold	74 USD	14/12/2024	16/12/2024
Steinhart Richard I CFO	0.55 USD	7,175 Sold	3,946 USD	17/09/2024	03/10/2024

Load More

Integrated EOD Stock Data and Insider Transactions Chart

Sign in or subscribe to include BioXcel Therapeutics, Inc. to your watchlist and receive automatic alerts for upcoming transactions.

Generate

The visibility of insider buy and sell transactions on this chart should not be the sole factor in your decision to buy or sell a particular stock. Always consider the following dynamic reports for a broader understanding of stock market activities:

• Insider Transaction Amount Distribution
• Insider Trading Seasonality
• Delta Correlation Analysis

 

Historical Performance

1M	3M	6M	1Y	3Y	5Y	All Time
-32%	-67%	-86%	-98%	-99%	0%	-96%

Last	52W Low	52W High	All-Time Low	All-Time High	β
2.50	1.18	11.68	1.18	1,034.08

Company Insiders

Person / Entity	Transactions	Turnover, USD	Average, USD	First	Last
Mehta Vimal	7	19,060.19	2,722.88	04/04/2024	16/12/2024
Steinhart Richard I	6	7,685.18	1,280.86	04/04/2024	16/12/2024
Yocca Frank	6	7,630.47	1,271.75	04/04/2024	16/12/2024
Rodriguez Javier	6	7,289.17	1,214.86	04/04/2024	16/12/2024
Wiley Matthew T.	4	6,562.40	1,640.60	04/04/2024	03/10/2024
O'neill Vincent	5	3,840.91	768.18	04/04/2024	16/12/2024

Insiders marked in yellow represent long-term insiders. These are individuals who have engaged in transactions for over 3 years and have conducted at least 10 transactions or reached a cumulative turnover of $1M USD. When examining transaction clusters, we prioritize those conducted by long-term insiders for analysis.

Connected Companies ³

Name	ISIN	Ticker
DAVITA INC.	US23918K1088	DVA

³ the firms where the current insiders have executed transactions.

Stock Advanced Metrics

Delta Correlation	subscribe 🔒
Upper Bound of Standardized Transaction Amount (ubsta), USD 4	subscribe 🔒

⁴ represents the maximum expected transaction amount for a company's insiders, calculated based on historical data. It provides insight into the typical range of insider transaction amounts and helps in identifying unusually large transactions.

⁵ a proprietary metric reflecting the consistency of insider trading behavior within a company. A higher discipline index suggests more regular and predictable insider transactions.